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INTRODUCTION 
 
The Southeastern United States has the highest HIV diagnosis rate of any US region.1 In 
2014, more than half of national HIV diagnoses reported were located in the Southern 
United States,2 which accounted for only 38% of the total US population.3 The Deep South 
(the nine-state region comprised of Alabama, Florida, Georgia, Louisiana, Mississippi, 
North Carolina, South Carolina, Tennessee, and Texas) 
has the highest rate of HIV-related deaths of any US 
region.4 From 2008-2013, 21,308 individuals in these 
states died from HIV as the underlying cause of death, 
representing 43% of deaths in the US where HIV was the 
underlying cause.5 In addition, each of the 9 Deep South 
states had higher death rates from HIV than the US 
average from 2008-2013.6 The Deep South region also 
leads in racial disparities. In 2013, nearly half (48%) 
of black gay/MSM diagnosed with HIV in the US 
lived in the Deep South and the HIV diagnosis rate 
for black women in the region was 37.5 per 
100,000 while the rate for white women was 2.6 
per 100,000.7 The statistics clearly indicate that 
individuals at risk of HIV infection in the Deep 
South, particularly African American men and women, are among those most in need of 
effective HIV prevention tools, and may stand to benefit most from the use of innovative 
new prevention strategies. 
 
Today, one of the most innovative and effective HIV prevention tools available is PrEP 
(pre-exposure prophylaxis), which refers to the use of antiretroviral medications (which 
historically have been used as a method of treatment for HIV-positive individuals after 
diagnosis) by HIV-negative individuals as a means to prevent HIV infection. Truvada, a 
drug created and marketed by Gilead Sciences, is the only approved PrEP medication, and, 
if taken regularly, has been shown to be an extremely effective method of preventing HIV 
                                                 
1
 Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection in the United States 
and Dependent Areas, 2014, Table 22; http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-
report-us.pdf. 
2 The US Census Bureau defines the South as including Alabama, Arkansas, Delaware, District of Columbia, Florida, 
Georgia, Kentucky, Louisiana, Maryland, Mississippi, Oklahoma, North Carolina, South Carolina, Tennessee, Texas, 
Virginia, West Virginia. 
3 US Census Bureau. United States Population Growth by Region. 2015; 
https://http://www.census.gov/popclock/data_tables.php?component=growth. Accessed October, 2015.  
4 Reif S, Safley D, McAllaster C, A CLOSER LOOK: Deep South has the Highest HIV-related Death Rates in the United States. 
2015. 
5 Reif S, Safley D, Wilson E, Whetten K, HIV/AIDS in the U.S. Deep South: Trends from 2008-2013, 2016. 
6 See Reif, footnote 5. 
7
 See Reif, footnote 5. 
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transmission.8 In the open label extension of the often-cited iPrEx study of PrEP efficacy, 
none of the men who took Truvada at least four times a 
week contracted HIV.9 And in a large study of PrEP 
users in a Kaiser Permanente Clinical Practice in San 
Francisco among 657 primarily gay and bi-sexual men, 
there were no new HIV diagnoses after two and a half 
years of observation.10  
 
In July of 2012, the US Food and Drug Administration (FDA) approved once-
daily Truvada for PrEP, and in May of 2014, the US Centers for Disease Control and 
Prevention (CDC) recommended that people at 'substantial risk' should consider PrEP to 
prevent HIV infection.11 The World Health Organization (WHO) has also recommended 
PrEP for people at ‘substantial risk’ of HIV infection.12 
 
Despite its remarkable effectiveness at preventing HIV transmission and the positive 
response with which it has been met by national and international health organizations, use 
of PrEP as a prevention strategy has been slow to take hold among some at-risk 
populations.13 The CDC estimates that 1.2 million people in the United States have 
indications for PrEP use based on their substantial risk of acquiring HIV (24.7% of men 
who have sex with men, 18.5% of persons who inject drugs and .4% of heterosexually 
active adults.)14 
 
A number of studies and surveys conducted primarily among vulnerable populations have 
revealed that barriers to PrEP use continue to exist. 
 
 
 
 
                                                 
8 Grant RM et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl Jour Med 
363(27):2587-2599, 2010.  
9 Grant RM et al. Results of the iPrEx open-label extension (iPrEx OLE) in men and transgender women who have sex with men: PrEP 
uptake, sexual practices, and HIV incidence. 20th International AIDS Conference, Melbourne, abstract TUAC0105LB, 2014. 
10
 Volk J, Marcus J, Phengrasamy T, Blechinger D, Nguyen D, Follansbee S, Hare C, No New HIV Infections with 
Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clinical Infectious Diseases 2015; 61(10):1601-3. 
11 Liz Highleyman, Truvada PrEP use rising in United States, especially among men, aidsmap.com, November 7, 2014, 
http://www.aidsmap.com/Truvada-PrEP-use-rising-in-United-States-especially-among-men/page/2919654/ (citing 
Flash C et al. Two years of Truvada for pre-exposure prophylaxis utilization in the US. International Congress of Drug Therapy in 
HIV Infection, abstract P198, Glasgow, 2014.); See also, Pre-exposure Prophylaxis for the Prevention of HIV Infection in the US-
2014: A Clinical Practice Guide, CDC 2014. 
12 WHO, Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV,  Sept. 2015, 
http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/  
13 See Highleyman, footnote 11. 
14
  Centers for Disease Control and Prevention. Vital Signs: Estimated Percentages and Numbers of Adults with 
Indications for Preexposure Prophylaxis to Prevent HIV Acquisition—United States, 2015, MMWR. November 27, 
2015/ 64(46);1291-1295. 
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PrEP USAGE BY DEMOGRAPHIC 
 
A recently-released Gilead Sciences survey analyzed retail pharmacy prescriptions and 
found that PrEP usage has increased 738% from January 2012 to December 2015.15 Major 
discrepancies exist between PrEP usage and HIV prevalence among specific demographic 
groups in the U.S. population. The breakdown of PrEP usage demographically underscores 
the need to reduce barriers to PrEP utilization for certain populations. 
 
Race & Ethnicity   | 
 
The Gilead PrEP analysis revealed significant racial disparities in PrEP utilization. Forty-
four percent of those diagnosed with HIV in the US in 2014 were African American, (27% 
were white, 23% were Hispanic, and 3% were Asian). In contrast, 74% of PrEP users were 
white; only 10% were African American, and 12% were Hispanic.16  
 
 
                                                 
15 Highleyman L, PrEP use exceeds 79,000 in US pharmacy survey, but some groups lagging behind, July 2016; 
http://www.aidsmap.com/PrEP-use-exceeds-79000-in-US-pharmacy-survey-but-some-groups-lagging-
behind/page/3072084/. 
16
 Bush S et. al., Racial Characteristics of FTC/TDF for Pre-exposure Prophylaxis (PrEP) Users in the US #2651, ASM Microbe 
2016 / ICAAC 2016, http://www.natap.org/2016/HIV/062216_02.htm.  
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Gender, Gender Identity | 
 
In 2015, 82% of new PrEP prescriptions were written for men.17 In 2012, women 
accounted for 49% of new PrEP prescriptions but by the third quarter of 2015, they 
accounted for only 11% of new prescriptions.18 One factor may be that women have less 
ability to access PrEP, as their OB/GYNs and reproductive health clinics may not be as 
knowledgeable about PrEP as the sexual health clinics that are serving MSM.19 Despite this, 
data suggests that use of PrEP during pregnancy and breastfeeding may protect both 
mother and baby from HIV infection. 20 A recent study in New York City and San 
Francisco also showed that women frequently chose to use PrEP when it was offered pre-
conception and during pregnancy and lactation.21 
 
Transgender women are at particularly high risk of HIV infection. Although accurate data 
is lacking, the CDC acknowledges high HIV prevalence among transgender women and the 
disparate impact of HIV on African-American transgender women.22 Researchers 
conducted an analysis of the iPrEx trial to investigate differences in PrEP results among 
transgender women.23 The study found that compared with MSM, transgender women 
more often reported behavior that results in higher rates of HIV transmission, including 
“transactional sex, receptive anal intercourse without a condom, or five or more partners 
within the past 3 months.”24 The study also found that while PrEP appears to be successful 
in preventing HIV transmission for transgender women when consistently used, there are 
adherence barriers.”25  
 
It is worth noting that the majority of US studies related to the efficacy of PrEP and 
potential barriers to effective PrEP utilization have been conducted among gay men and 
other men who have sex with men (gay/MSM), since gay/MSM are widely considered most 
at risk of acquiring HIV and of benefiting from PrEP in the US. Despite the fact that 
                                                 
17 U.S. PrEP Users Likely Exceeded 80,000 by End of 2015, poz.com, July 21, 2016, https://www.poz.com/article/us-
prep-use-likely-80000-end-2015. 
18
 See Bush, Footnote 16. 
19
 Highleyman L, PrEP use exceeds 79,000 in US pharmacy survey, but some groups lagging behind, aidsmap.com, July 
19, 2016, http://www.aidsmap.com/PrEP-use-exceeds-79000-in-US-pharmacy-survey-but-some-groups-lagging-
behind/page/3072084/. 
20
 Highleyman L, Study looks at use of PrEP during pregnancy and breastfeeding, aidsmap.com, September 1, 2016, 
http://www.aidsmap.com/Study-looks-at-use-of-PrEP-during-pregnancy-and-breastfeeding/page/3081236/. 
21
 Seidman, D. et. Al. Use of HIV pre-exposure prophylaxis during the preconception, antepartum and postpartum 
periods at two United States Medical Centers, AmJObstetGynecol 2016.  
22 HIV Among Transgender People, April 2016, http://www.cdc.gov/hiv/pdf/group/gender/transgender/cdc-hiv-
transgender.pdf.  
23
 Deutsch MB et. al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. The 
Lancet HIV 2015, 2:512-519. 
24
 See Deutsch, Footnote 23. 
25
 See Deutsch, Footnote 23. 
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certain populations of cisgender women, who account 
for 20% of all new HIV diagnoses in America, and 
transgender women are also at high risk of acquiring 
HIV, US data regarding the efficacy and uptake of PrEP 
among women is underdeveloped.26 Nonetheless, 
cisgender women who have been surveyed about their 
knowledge and attitudes towards PrEP had reactions similar to those recorded among 
gay/MSM, with some expressing initial frustration about their lack of knowledge of the 
availability of PrEP, and many articulating a willingness to learn more about the drug and 
an interest in utilizing it as a prevention method if they could gain access to it.27 
Furthermore, women surveyed about PrEP expressed many of the same reservations about 
the drug and identified many of the same potential barriers to widespread utilization that 
are explored in depth in the section below, including concerns about cost, side-effects, 
stigma, and potential lack of access due to medical mistrust or other factors.28 
 
Age   | 
 
Individuals under the age of 25 make up 22% of new HIV diagnoses overall, with 80% of 
these being MSM and over half of those being African American.29 Despite this, Gilead 
found that individuals using PrEP were on average 36 years old 30 and only about 8% of 
those beginning PrEP were under the age of 25.31 Though 28% of women using PrEP were 
under 25, only 11% of the men fit into that category.32 This was comparable across all racial 
and ethnic groups. 
 
Region of Residence   | 
 
In 2014, 51% of new HIV diagnoses occurred in the US South.33 Although the South has a 
significant urban epidemic, in 2014, the South had almost three times the number of newly 
diagnosed people living outside the large urban areas (5183) than all other US regions 
                                                 
26 See Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, Attitudes, and Likelihood of Pre-Exposure Prophylaxis 
(PrEP) Use Among US Women at Risk of Acquiring HIV.AIDS Patient Care and STDs. 2015;29:12-110. 
27 See Auerbach, footnote 26. 
28 See Auerbach, footnote 26. 
29
 Centers for Disease Control and Prevention: HIV Among Youth, April 2016, 
http://www.cdc.gov/hiv/pdf/group/age/youth/cdc-hiv-youth.pdf.  
30
 Highleyman L, AIDS 2016: San Francisco and New York Lead in PrEP Use, betablog.org, July 20, 2016, 
http://betablog.org/aids-2016-san-francisco-new-york-lead-prep-use/. 
31
 Highleyman L, PrEP use is rising fast in US, but large racial disparities remain, aidsmap.com, June 24, 2016, 
http://www.aidsmap.com/PrEP-use-is-rising-fast-in-US-but-large-racial-disparities-remain/page/3065545/. 
32
 Highleyman L, AIDS 2016: San Francisco and New York Lead in PrEP Use, betablog.org, July 20, 2016, 
http://betablog.org/aids-2016-san-francisco-new-york-lead-prep-use/. 
33
 Centers for Disease Control and Prevention, HIV Surveillance Report: 
http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-us.pdf 
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combined (1756). 34 Gilead’s survey data shows that PrEP uptake has primarily been in 
large US cities and is not wide-spread in smaller urban and rural regions, particularly in the 
US South. Five states (California, New York, Texas, Florida and Illinois) with large urban 
epidemics accounted for more than half of all PrEP prescriptions nationwide from 2012 to 
the third quarter of 2015 according to Gilead’s utilization data.35  
 
BARRIERS TO WIDESPREAD PrEP UTILIZATION IN THE SOUTH 
Lack of Awareness   | 
 
The first and perhaps most prohibitive barrier to widespread PrEP utilization is a simple 
lack of awareness of the drug’s existence among at-risk populations.  
 
In order for PrEP to be effectively employed as an HIV prevention strategy, potential 
PrEP users must know about it, understand its risks and benefits, and be willing to take it.36 
Some studies examining PrEP underutilization have shown that many high-risk individuals 
who would be excellent candidates for PrEP have not taken it simply because their 
knowledge about it is limited.37  
 
In one study conducted among young gay/MSM—by far the most high-risk population of 
any demographic—in 2013, only 27% of study participants reported prior awareness of 
PrEP.38 A 2014 survey conducted on Manhunt, one of the largest social-networking sites 
geared towards men who have sex with men, found that only 3.1% of almost 9000 
gay/MSM respondents had used PrEP and that “substantial numbers” had not heard of 
it.39 A 2015 study conducted among young gay/MSM of color found that only 50% of 
participants were aware of PrEP prior to their participation in the study.40 Among 
participants in this study who did report prior knowledge of PrEP, however, this 
information was obtained from a variety of sources including the CDC website, Facebook, 
                                                 
34
 Centers for Disease Control and Prevention, HIV Surveillance in Urban and Nonurban Areas, 
http://www.cdc.gov/hiv/library/slideSets/index.html.  
35
 See Highleyman L, Footnote 19. 
36 Castel AD, Magnus M, Greenberg AE. Pre-exposure prophylaxis for human immunodeficiency virus: the past, present, 
and future. Infect Dis Clin North Am. 2014; 28:563–583. 
37 Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV 
prevention: a narrative review. Ann Intern Med. 2012; 157:490–497. 
38 Bauermeister JA, Meanley S, Pingel E, Soler JH, Harper GW. PrEP awareness and perceived barriers among single 
young men who have sex with men. Current HIV Research. 2013; 11:520. 
39 Mayer KH, Oldenburg CE, Novak DS, Krakower DS, Mimiaga MJ. Differences in PrEP knowledge and use in U.S. 
MSM users of a popular sexual networking site surveyed in August 2013 and January 2014. R4P Conference; A91. 2014 
October 28–31; Cape Town, South Africa. 
40 Perez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. ACCEPTABILITY OF PrEP UPTAKE AMONG 
RACIALLY/ETHNICALLY DIVERSE YOUNG MEN WHO HAVE SEX WITH MEN: THE P18 STUDY. AIDS 
Education and Prevention. 2015; 27:112-125. 
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television reports/news, information obtained from community health agencies, and 
friends, and from doing their own, independent research.41  
 
Across existing studies, awareness of PrEP has been 
markedly lower among men of color, those who are 
less highly educated, and those whose primary care 
providers are not aware of the fact that they have sex 
with men.42 Though men with more education or a 
higher income were much more likely to have heard of 
PrEP, they were not, according to one report, any 
more likely to have used it.43 And in a study conducted among at-risk women (primarily 
African-American women) in six US cities, less than 10% of those surveyed expressed prior 
knowledge of PrEP as a preventative measure.44 Among those high-risk individuals who 
were not previously aware of PrEP as an HIV prevention strategy, many who participated 
in studies or surveys about PrEP expressed interest in using it upon learning of its potential 
for preventing infection.45  
 
Although lack of awareness of PrEP among many high-risk populations remains one of the 
primary barriers to widespread utilization, evidence suggests that in recent years, knowledge 
of PrEP as a prevention strategy has noticeably increased.46 According to data obtained by 
the CDC through large internet-based surveys of gay, bisexual and other MSM living in the 
United States (who were recruited via dating apps and websites, social media and gay 
websites), awareness of PrEP as a prevention strategy increased significantly from 45% in 
2012 to 68% in 2015.47  
 
                                                 
41 See Perez-Figueroa, footnote 40.  
42 Barash EA. Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride 
event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010; 24:689–691; Mimiaga MJ. Case P. Johnson 
CV. Safren SA. Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report 
having sex with men: Limited knowledge and experience but potential for increased utilization after education. J Acquir 
Immune Defic Syndr. 2009; 50:77–83. 
43 Peabody R, Rapid rise in PrEP awareness in US gay men, but only 5% have used PrEP, aidsmap.com, March 10, 2016, 
http://www.aidsmap.com/Rapid-rise-in-PrEP-awareness-in-US-gay-men-but-only-5-have-used-PrEP/page/3042435/. 
44 See Auerbach, footnote 26.  
45 See Auerbach, footnote 26; See Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH (2009) Preexposure 
antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and 
experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 50: 77-83. 
46 See Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited Awareness and Low 
Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social 
Networking Site. PLoS One. 2012; 7(3):e33119. http://dx.doi.org/10.1371/journal.pone .0033119; Mayer KH, Levine K, 
Grasso C, Krakower DS, Mimiaga M. Recent increases in PreP utilization among men who have sex with men in a 
Boston community health center 2011–2014: transition from research to clinical practice. Conference on Retroviruses and 
Opportunistic Infections (CROI); 2015 February 23–26; Abstract; Seattle, WA. 
47 Delaney KP et al. Awareness and Use of PrEP Appear to Be Increasing Among Internet Samples of US MSM. Conference on 
Retroviruses and Opportunistic Infections (CROI 2016), Boston. Abstract 889, 2016. 
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Even as levels of awareness of PrEP are increasing, however, levels of actual PrEP 
utilization (though also increasing) remain low. The most recent survey regarding PrEP 
awareness among American gay/MSM conducted by the CDC in 2015, 68% of 
respondents reported knowledge of the existence of PrEP, and 50% stated that they would 
be willing to use PrEP (up from 39% in 2012), but less than 5% reported having actually 
used it in the past twelve months (up from 0.5% in 2012).48 Further, rates of PrEP use 
varied distinctly among respondents based on their location—while 17% of respondents 
who live in San Francisco reported using PrEP as prevention (along with 11% in Seattle, 
12% in New York City, 16% in Washington DC and around 8% in Boston, Philadelphia, 
Chicago and Los Angeles), only 2% of respondents in rural areas reported doing the 
same.49 This data indicates that even as more individuals become aware of PrEP as a tool 
for preventing HIV infection, there are other barriers in place, particularly for those who 
live in smaller cities and more rural parts of the country (like much of the Deep South), that 
prevent eligible candidates for PrEP from taking advantage of it.  
 
Lack of Access   | 
 
For many high-risk individuals who may qualify as good candidates for PrEP, another 
barrier to utilization of the drug is lack of access. In order to obtain a prescription for 
PrEP, a prospective user must have ready access to a clinical care provider who is willing to 
prescribe it, must themselves be willing to discuss PrEP with their provider and be willing 
to undergo regular check-ups, as well as HIV tests and other lab tests, and must have 
access to a pharmacy or other location where the medication can be attained. Many 
individuals who would like to and would benefit from accessing PrEP may be unwilling or 
unable to take all the steps necessary to obtain access to it.  
  
In numerous studies and surveys conducted among PrEP-eligible populations, concern 
about access to PrEP was among the most common barriers cited by participants as a 
reason they might not utilize it.50 Many at-risk individuals are not linked to medical care 
relating to sexual health or otherwise, so the concept of having to visit a medical health 
professional and undergo medical tests regularly may seem daunting or overly 
complicated.51 Similarly, some individuals, whether they are linked to care or not, may 
simply not want to go through all of the necessary requirements to obtain a PrEP 
prescription for any number of reasons, which may include general mistrust of medical 
professionals (more common among people of color), perception (whether accurate or not) 
that doctors do not want to talk about sexual health and therefore will not initiate these 
                                                 
48 See Delaney, footnote 47. 
49 See Delaney, footnote 47. 
50 Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee S, Leibowitz AA. Motivators, concerns, and barriers to adoption 
of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male 
relationships. AIDS Care. 2011; 23:1136-1145. 
51 See Brooks, footnote 50.  
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conversations, or broader anxiety about/unwillingness to discuss sexual 
history/practices/needs with a physician.52  
Furthermore, some prospective PrEP users may have 
limited access to the drug because they have limited 
access to medical care in general (for financial or 
other reasons), or because they live in an area where 
there are no nearby PrEP/HIV clinics and no 
medical providers willing to prescribe PrEP.53 
 
The fact that some medical providers are unwilling to 
prescribe PrEP or will only prescribe it in limited circumstances can be a severe barrier for 
many individuals seeking access to PrEP, so it is worth additional consideration. Though 
general knowledge about and support for PrEP have increased since the FDA approved 
Truvada and the CDC released the prescribing guidelines, knowledge of PrEP among 
providers has increased only slightly,54 and actual prescribing rates remain relatively low.55 
In one survey of HIV providers in Washington D.C. and Miami (cities with above-average 
rates of HIV) regarding their knowledge and attitudes about PrEP and willingness to 
provide it, 53% of surveyed providers agreed that PrEP is effective as an HIV prevention 
strategy, but only 17% reported ever prescribing it.56 In a subsequent national survey of 
infectious disease specialists, 74% of those surveyed supported PrEP as an HIV prevention 
strategy, but only 9% reported ever prescribing it.57  An earlier online, cross-sectional 
survey of generalist and HIV specialist physicians in Massachusetts found that 95% of 
                                                 
52 Bernstein KT, Liu KL, Begier EM, Koblin B, Karpati A, et al. (2008) Same-sex attraction disclosure to health care 
providers among New York City men who have sex with men: implications for HIV testing approaches. Arch Intern Med 
168: 1458–1464. doi: 10.1001/archinte.168.13.1458; Mimiaga MJ, Goldhammer H, Belanoff C, Tetu AM, Mayer KH 
(2007) Men who have sex with men: perceptions about sexual risk, HIV and sexually transmitted disease testing, and 
provider communication. Sex Transm Dis 34: 113–119. doi: 10.1097/01.olq.0000225327.13214.bf; Centers for Disease 
Control, Prevention (1994) HIV prevention practices of primary-care physicians–United States, 1992. MMWR Morb 
Mortal Wkly Rep 42: 988–992; Loeb DF, Lee RS, Binswanger IA, Ellison MC, Aagaard EM (2011) Patient, resident 
physician, and visit factors associated with documentation of sexual history in the outpatient setting. J Gen Intern Med 26: 
887–893. doi: 10.1007/s11606-011-1711-z; Montano DE, Phillips WR, Kasprzyk D, Greek A (2008) STD/HIV 
prevention practices among primary care clinicians: risk assessment, prevention counseling, and testing. Sex Transm Dis 
35: 154–166. doi: 10.1097/olq.0b013e3181574d97; Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger 
CL. From Efficacy to Effectiveness: Facilitators and Barriers to PrEP Acceptability and Motivations for Adherence 
among MSM and Transgender Women in New York City. AIDS patient care and STDs. 2013; 27:248-254. 
53 See http://www.prepwatch.org/policies-and-programs/local-programs/ for a list of state-by-state PrEP providers.  
54 White JM, Mimiaga MJ, Krakower DS, et al. Evolution of Massachusetts physician attitudes, knowledge, and experience 
regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012; 26:395–405. 
55 Rawlings K, Mera R, Pechonika A, et al. Status of Truvada (TVD) for HIV Pre-Exposure Prophylaxis (PrEP) in the United 
States: An Early Drug Utilization Analysis. Denver, CO: ICAAC; 2013. 
56 Castel AD, Feaster DJ, Tang W, et al. Understanding HIV Care Provider Attitudes Regarding Intentions to Prescribe 
PrEP. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015; 70:520-528. 
57 Karris MY, Beekmann SE, Mehta SR, et al. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on 
the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014; 58:704–712. 
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participants said they would be willing to prescribe PrEP in theory, but only 4% had 
actually prescribed it in the past.58  
  
Providers who have not prescribed PrEP mentioned a laundry list of reasons as to why, 
including concerns over issues such as drug-related toxicities, the potential development of 
drug resistance, potential for funds to be diverted from behavioral HIV programs to 
biomedical programs, concerns over the efficacy data, and fear that PrEP could increase 
HIV risk behavior.59 A 2013 survey of HIV health care providers in the United States 
found that drug resistance, risk compensation, and adherence were respondents' top 3 
concerns, and drug cost was the fourth most common concern.60 Other studies have also 
found that one of the most common perceived barriers to PrEP provision among 
infectious disease physicians was the belief that the protocol required for effective 
utilization of the drug is too time-consuming.61 
 
Studies have shown that while HIV incidence is higher among African American MSM, this 
group tends to report less risky sexual behavior and drug use than white men.62 As such, 
many of the prescribing guidelines and risk factors will not apply to this group, leading to 
less access to PrEP for a high risk demographic.63 “Clinicians may need to consider other 
factors besides risk behaviors, such as HIV incidence and prevalence in sub-groups of their 
communities, when considering prescribing PrEP.”64 
 
Additional surveys of HIV providers across America have indicated that many are 
hesitant/unwilling to prescribe PrEP based on previous encounters with HIV-positive 
patients who did not adhere to life-sustaining treatment and with HIV-negative patients 
who did not adhere to post-exposure prophylaxis regimens despite an awareness that they 
were at high-risk for HIV acquisition.65 There seems to be a belief among many HIV 
providers, perhaps shaped by these past experiences, that adherence to PrEP would be low 
even if they were to prescribe it.66 Additionally, lack of specific requests for PrEP by 
patients are perceived by providers as proof of patient ambivalence and community apathy 
regarding PrEP, which functions as a sort of self-fulfilling prophecy, confirming in their 
                                                 
58 White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and 
experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012; 26:395–405. 
59 See White, footnote 58. 
60 Tellalian D, Maznavi K, Bredeek UF, et al. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of 
HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013; 
27:553–559. 
61 See Karris, footnote 57. 
62
 Hoots B. Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With 
Men—20 US Cities, 2014, Clin Infect Dis. 2016 Sep 1: 63(5): 672-677. 
63
 See Hoots, Footnote 62. 
64
 See Hoots, Footnote 62. 
65 Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV Providers’ Perceived Barriers and Facilitators to 
Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study. AIDS and Behavior. 2014; 18:1712-1721. 
66 See Krakower, footnote 65. 
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minds the already present notion that PrEP is ineffective or irrelevant.67 Despite these 
misconceptions, however, most HIV providers believed that PrEP is efficacious if used 
consistently and that patient requests would motivate them to prescribe it.68 The providers 
also suggested they would be more willing to prescribe PrEP if they knew their colleagues 
were also doing so.69  
 
Importantly, significant numbers of HIV providers have expressed that they are not in a 
position to prescribe PrEP since the majority of patients seen by HIV providers are HIV 
positive and therefore not candidates for PrEP. They also believe that, as a matter of 
general principle, primary care providers are better situated to make such decisions with 
their patients.70 Surveyed primary care providers suggested the opposite: it is their belief 
that HIV specialists are better situated to prescribe PrEP.71 These differing opinions among 
categories of providers about who is in the best position to prescribe PrEP to eligible 
patients create a problematic “purview paradox,” which could limit the accessibility of 
PrEP for a number of prospective users.72  
 
Cost   | 
 
The cost of PrEP is another barrier that may inhibit those individuals who could most 
benefit from PrEP from gaining access to it. A prescription for Truvada for PrEP costs 
roughly $1,300 per month.73 The good news is that Medicaid and private insurance do 
generally cover the costs of PrEP. For those who are not privately insured, Gilead also 
offers a prescription assistance program that helps cover the costs of Truvada prescriptions 
for those eligible.74 Gilead also offers a co-pay assistance program to help meet the needs 
of individuals who are privately insured and who may not be able to afford the co-pays 
associated with a Truvada prescription.75 Furthermore, a small number of community-
based organizations in some American cities, like Healthy San Francisco in San Francisco, 
which seek to make healthcare available to uninsured residents of the city will cover the 
cost of a PrEP prescription for individuals interested in utilizing PrEP as an HIV 
prevention strategy but who could not otherwise afford the medication.76 
 
Despite the fact that some financial assistance options are available to prospective PrEP 
users to help cover the costs of the drug, the fact remains for many individuals, particular 
                                                 
67 See Krakower, footnote 65. 
68 See Krakower, footnote 65. 
69 See Krakower, footnote 65. 
70 See Krakower, footnote 65. 
71 See Krakower, footnote 65. 
72 See Krakower, footnote 65. 
73 The Questions About PrEP, prepfacts.org, http://men.prepfacts.org/the-questions/.  
74 Gilead, Truvada for PrEP Medication Assistance Program, http://www.gilead.com/responsibility/us-patient-
access/truvada%20for%20prep%20medication%20assistance%20program.  
75 Gilead, Paying for Truvada, http://www.truvada.com/truvada-patient-assistance. 
76 See Healthy San Francisco, http://healthysanfrancisco.org/.  
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uninsured individuals, gaining access to PrEP can still be a costly and, in some cases, 
prohibitively complicated, process. Successful utilization of PrEP requires a number of 
actions beyond just taking the daily medication—including frequent doctor visits and 
regular HIV tests and other lab tests—all of which involve additional expenses that may or 
may not be covered by insurance or other financial assistance programs.  
 
The costs associated with PrEP are often cited by potential PrEP users as one of the most 
significant barriers to meaningful PrEP utilization.77 In one study conducted among high-
risk gay/MSM, 80% of participants indicated that they would be likely to use PrEP if it was 
provided free of charge, but 89.3% reported that they would be unlikely to use PrEP if it 
cost money out of pocket each month.78 In another study, 416 high-risk gay/MSM were 
provided with educational counseling regarding rates of HIV transmission and the 
effectiveness of PrEP as a prophylactic medicine.79 Each participant was then presented for 
HIV testing and was offered a prescription for PrEP.80 Of the 416, only 2 participants 
(both of whom had private insurance) accepted the prescription and eventually accessed 
PrEP.81 When the remaining participants were surveyed regarding why they did not accept 
the PrEP prescription that was offered to them, 48% reported cost as a major barrier.82  
 
Private insurance and Medicaid generally provide coverage for PrEP 83 and Gilead’s Co-pay 
Assistance Program (CAP) provides assistance for insurance co-pays up to $3,600 per 
year.84 Most Southern states, however, have not expanded their Medicaid programs under 
the Affordable Care Act (ACA.) People with incomes below 100% of the federal poverty 
level remain uninsured because they fall into the so-
called coverage gap. They earn too little to qualify for 
ACA insurance subsidies and they aren’t covered by 
Medicaid because they live in a state without an 
expanded Medicaid program.  The Kaiser Family 
                                                 
77 Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee S, Leibowitz AA. Motivators, concerns, and barriers to adoption 
of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male 
relationships. AIDS Care. 2011; 23:1136-1145; Bauermeister JA, Meanley S, Pingel E, Soler JH, Harper GW. PrEP 
awareness and perceived barriers among single young men who have sex with men. Current HIV research. 2013; 11:520; 
Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From Efficacy to Effectiveness: Facilitators and 
Barriers to PrEP Acceptability and Motivations for Adherence among MSM and Transgender Women in New York 
City. AIDS patient care and STDs. 2013; 27:248-254. 
78 Gersh JK, Fiorillo SP, Burghardt L, Nichol AC, Thrun M, et al. (2014) Attitudes and Barriers towards Pre-Exposure 
Prophylaxis (Prep) among High- Risk HIV-Seronegative Men who have Sex with Men. J AIDS Clin Res 5:335. 
doi:10.4172/2155-6113.1000335. 
79 King HL, Keller SB, Giancola MA, et al. Pre-Exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE 
Study). AIDS and Behavior. 2014; 18:1722-1725. 
80 See King, footnote 79. 
81 See King, footnote 79. 
82 See King, footnote 79. 
83
 http://www.healthline.com/health-news/hiv-prevention-truvada-prep-covered-by-most-insurers-050814  
84
 https://www.gileadadvancingaccess.com/hcp/financial-assistance/copay-support  
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Foundation estimates that 90% of people in the coverage gap live in the South.85 
 
Because gaining access to PrEP can be expensive, especially for those without insurance, 
many high-risk individuals, particular people of color and those of lower socio-economic 
status do not consider PrEP a viable option for themselves.86 Some have even reported 
feeling that PrEP is essentially a “white man’s drug” that is beneficial only for the wealthy, 
white gay men they feel are less likely to face financial barriers in obtaining PrEP.87  
 
Stigma   | 
 
Another factor that is known to negatively impact meaningful PrEP implementation is 
stigma, which can discourage PrEP use among high-risk individuals on a number of 
levels.88  
 
Many individuals who could benefit from PrEP may choose to avoid it simply because it is 
an HIV-related medication. Because HIV remains heavily stigmatized today, particularly in 
the Deep South,89 even members of the most vulnerable 
populations may not want to be associated with it in order 
to avoid being subjected to stigma-related gossip and 
rejection.90 Furthermore, the fact that HIV is also in many 
cases closely associated with other stigmatized subjects 
like homosexuality, sex work, and drug use may further 
alienate potential PrEP users and prevent them from 
seeking access to PrEP for fear that an association with 
one or more of these categories will be attributed to them.91 Indeed, studies and surveys of 
attitudes about PrEP use held by at-risk individuals reveal that many potential PrEP users 
do not take advantage of PrEP availability for fear that if they are seen doing so, it will 
make others think (or realize) that they are gay (this concern is especially common among 
young gay/MSM who are not out to their family or friends), that it will make others think 
that they are HIV positive, or that it will make their partner/spouse believe that they are 
                                                 
85
 Garfield R, Damico A, The Coverage Gap: Uninsuraed Poor Adults in States that Do Not Expand Medicaid, Henry J. Kaiser 
Family Foundation, Jan. 21, 2016. http://kff.org/health-reform/issue-brief/the-coverage-gap-uninsured-poor-adults-in-
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86 See Perez-Figueroa, footnote 40. 
87 See Perez-Figueroa, footnote 40.  
88 See Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions 
related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and 
implications for access. AIDS Behav. 2014; 18(2):226–240. 
89
 Reif S, Sullivan K, Wilson E, Berger M, HIV/AIDS Care and Prevention Infrastructure in the U.S. Deep South, Feb. 2016, 
https://southernaids.files.wordpress.com/2016/03/hiv-aids-care-and-prevention-infrastructure-in-the-u-s-deep-
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90 Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for 
action. Soc Sci Med. 2003; 57(1):13–24; Haire BG, Preexposure prophylaxis-related stigma: strategies to improve uptake 
and adherence - a narrative review. HIV/AIDS : Research and Palliative Care. 2015; 2015:241-249. 
91 See Parker, footnote 90.  
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engaging in sex outside of the relationship.92 These concerns were found to be particularly 
common among young African American men.93  
 
Potential PrEP users may be discouraged from accessing the drug because of relentless 
opposition by the AIDS Healthcare Foundation, led by Michael Weinstein, to the use of 
PrEP.  Though no meaningful evidence has been produced to support the idea that 
widespread PrEP availability will engender more high-risk behavior, Weinstein argues that 
PrEP is little more than a “party drug” that will encourage high-risk individuals to engage in 
unsafe sexual practices further stigmatizing the use of PrEP by potential users.94  
 
A number of PrEP users have confirmed that they have in fact encountered and 
experienced many of the kinds of stigma that potential PrEP users have identified as 
deterrents to utilizing PrEP as a prevention strategy from medical providers, friends, sex 
partners, and others.95 Combating this kind of stigma, some experts have suggested, will 
require a multi-faceted approach, including social-marketing campaigns, education for 
health care providers, and a broad recognition of PrEP users as individuals proactively 
using proven prevention strategies.96 
 
Adherence   | 
 
Another barrier that may inhibit eligible candidates for 
PrEP is the requirement of adherence. In order for 
PrEP to be effective prophylaxis, it must be taken 
regularly—it will not function as an adequate 
preventative measure if only taken on an as-needed 
basis. There are gender differences in the level of adherence that may be required. A recent 
study by University of North Carolina researchers sheds some light on why PrEP may be 
less effective in women than in gay/MSM. Researchers tested how well PrEP is absorbed 
                                                 
92 Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities 
most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ open. 2014;4:e005717-e005717; 
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2014; 11:e1001613. 
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by the rectum, vagina, and cervix while also looking at the levels of DNA material used by 
HIV to reproduce that was present. Based on the results and using modeling, researchers 
calculated the minimal PrEP dose that women and gay/MSM would need to take to 
achieve protection. They estimated that women would need to take PrEP almost daily 
while gay/MSM could conceivably achieve protection with two to three doses per week.97 
Despite this study and though the iPrEx Study found that participants who took PrEP 
medication at a frequency of approximately four times per week had a comparable level of 
protection to those who took the medication on a daily basis, it is still recommended that 
all those seeking to use PrEP as a prevention strategy take the medication once a day in 
order maintain the highest likelihood of avoiding infection.98  
 
In studies and surveys conducted among high risk populations that asked participants 
whether they would be likely to adhere to the required PrEP regimen, many said they 
would not, and offered a number of reasons why. First, the notion of having to take a pill 
every day was simply deemed burdensome by many and “difficult to sustain over the long 
term.”99 Some participants suggested that they would be unlikely to adhere because they 
just do not like taking pills, while others commented that, because of irregular daily 
schedules/sleep patterns or other reasons, they would be likely to forget to take the pills on 
a consistent basis.100 Among those who voiced concern along these lines, as-needed 
condom usage was generally pointed to as an easier to remember and less burdensome 
prevention strategy than daily PrEP usage.101  
 
Real world research that looked at PrEP adherence, 
however, found that adherence levels were generally 
high. In a study that examined PrEP adherence among 
557 gay/MSM in San Francisco, Washington, D.C. and 
Miami clinics, “80% - 85% had achieved protective drug 
levels at follow-up visits,” according to Albert Liu, MD, 
director of HIV Prevention Studies at the San Francisco 
Department of Health.102 Lower rates of adherence, 
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however, were found among African-Americans, young people, and those without stable 
housing.103 One study concluded that young men 
who have sex with men in the US “may need access 
to PrEP in youth-friendly settings with tailored 
adherence support and potentially augmented visit 
schedules.” 104 A recent study found that African 
American MSM would utilize and adhere to PrEP if 
engaged and supported in “culturally appropriate” 
ways by providers.105 Further research into the 
factors that contribute to the adherence gap and effective interventions must be considered 
seriously in any effort to understand and combat barriers to meaningful PrEP usage. 106 
 
Attitudes and Misconceptions about Risk / PrEP   | 
 
Other barriers that may prevent good candidates for PrEP from utilizing it as a prevention 
strategy are general attitudes and concerns about the risk of HIV transmission and about 
the drug itself. In studies that looked at attitudes of young gay/MSM and transgender 
women107, some individuals who were eligible for PrEP did not think it was necessary or 
would benefit them due to potentially incorrect perceptions about their own susceptibility 
to risk.108 Some commented that other methods of prevention, like condoms, are effective, 
and are also cheaper, more widely available, and less burdensome to use than PrEP, so the 
need for PrEP is simply not present in their lives.109 Though Truvada has been shown to be 
generally well tolerated by users,110 others expressed concern about possible side effects and 
the possibility of developing resistance to the medication111 indicating the need for more 
widespread education about PrEP. 
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In a United Kingdom study with gay/MSM and African heterosexual participants, some 
PrEP candidates indicated that PrEP would not meet their needs as it does not protect 
against sexually transmitted diseases other than HIV and does not prevent pregnancy.112 
Despite evidence to the contrary, others worried that, as a matter of policy, widespread 
PrEP use would encourage high-risk behaviors among high risk individuals.113 
 
Further education about the extraordinary protective benefits of PrEP against HIV 
transmission and wide-reaching recommendations that PrEP be used combination with 
other measures such as condoms to prevent other STIs and contraceptives to avoid 
pregnancy, are needed. 
 
CONCLUSIONS AND STEPS FORWARD 
As discussed in this report, the benefits of PrEP are well established. It is critical that we 
overcome the multi-faceted barriers to achieving widespread PrEP utilization among 
vulnerable populations. Many of these barriers may be especially prohibitive in the South, 
where rates of poverty are higher than the national average, conservative attitudes about 
sex and HIV may heighten stigma concerns, where few states have expanded their 
Medicaid programs under the Affordable Care Act, and health outcomes are generally 
poor.  
 
We know that PrEP, when taken as prescribed, is an effective tool to prevent HIV 
transmission. Reliance on condom use alone is unlikely to eliminate or even substantially 
decrease new HIV diagnoses in the US, especially in the South where rates of new 
diagnoses are highest. Despite the wide spread availability of condoms in recent years, the 
rates of new HIV diagnoses have remained constant 
at around 50,000 per year.114 According to the most 
recent data released by the CDC, which reports that 
an estimated 44,784 individuals were diagnosed with 
HIV in the US in 2014, rates of new HIV diagnoses 
show no meaningful signs of declining unless new 
preventative measures like PrEP increase.115 Because 
of this, the significance of working to eliminate 
barriers to widespread utilization of PrEP cannot be overstated.  
 
                                                 
112 See Young, footnote 92.  
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Some progress is certainly being made, primarily in larger urban areas. First, the number of 
PrEP clinics that offer access to Truvada for eligible candidates throughout the South is 
increasing.116 For example, in February of 2016, the Health Services Department of Fulton 
County, Georgia partnered with Gilead Sciences to launch a new PrEP clinic in Atlanta 
where prescriptions for once-daily Truvada, as well as regular HIV tests and other required 
lab tests will be offered eligible PrEP candidates free of 
charge.117 The new PrEP clinic represents a major step 
forward in what Fulton County Commission Chair John 
Eaves called the county’s “aggressive approach” to 
combatting HIV. “We are going to be a leader like San 
Francisco, we are going to be a leader like New York City 
in terms of being aggressive,” Eaves commented, stating 
at the clinic’s opening “We are here because Fulton 
County cares. We are here because we have one tool in the toolbox to address the issue.”118 
The idea that PrEP is now an important “tool” that can be utilized to help profoundly 
reduce rates of HIV transmission is beginning to take hold across the South, as a number 
of other major cities are poised to or have already launched clinics similar to Fulton 
county’s, a trend which will hopefully prompt a noticeable decline in the number of new 
HIV diagnoses in the South. 119 
 
In addition to the increase in the number of clinics providing access to PrEP that are now 
opening across the South, the CDC has also recently introduced funding opportunities that 
are available to state and local health departments to encourage the provision of PrEP and 
PrEP-related services to at-risk individuals in larger cities. Among these funding 
opportunities are CDC-RFA-PS15-1509,120 the purpose of which is to support health 
departments to collaborate with CBOs, healthcare clinics and providers, behavioral health 
providers, and social services providers to develop comprehensive models of prevention, 
care, behavioral health, and social services models for gay/MSM of color living with or at 
risk for HIV acquisition, and CDC-RFA-PS15-1506, the purpose of which is to support 
state and local health departments to implement PrEP and Data to Care demonstration 
projects for populations of gay/MSM and transgender persons at high risk for HIV 
infection, particularly persons of color.121 In its most recent distribution of funds under 
these categories, the CDC awarded a number of grants to health departments in the South, 
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including CDC-RFA-PS15-1509 grants to the Virginia State Health Department, the 
Alabama Department of Public Health, and the Louisiana Department of Health, and 
CDC-RFA-PS15-1506 grants for PrEP support to large urban areas in Louisiana, Maryland, 
Virginia, Tennessee, and Texas.  
 
The distribution of federal grants like these, which will be used to support PrEP provision 
in a number of Southern states and cities, also represents an affirmative step towards 
eliminating many of the primary barriers that are limiting PrEP utilization in the South. 
Efforts like these to combat barriers to PrEP need to continue and be expanded to include 
smaller cities and rural areas and vulnerable populations with heavy HIV burden so that the 
South will continue to make progress towards achieving widespread utilization of PrEP 
among high-risk populations. In order to facilitate the continuance of this positive change, 
a number of recommendations for how to remove barriers and further increase PrEP 
utilization in the South are offered below.  
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RECOMMENDATIONS: 
 
TO INCREASE PrEP UTILIZATION IN THE SOUTH AND THE US. 
Federal Policy Recommendations 
 
 The Centers for Disease Control and Prevention (CDC) should work with the US 
Department of Health and Human Services, state health departments and 
community-based organizations to: 
o Develop best practices to reach at-risk persons who could benefit from PrEP;  
o Develop best practices to reach and train primary care medical providers on 
PrEP; 
o Develop a PrEP surveillance system to measure PrEP utilization. 
 
 The CDC should ensure that CDC funding focused on PrEP: 
o Allows for flexibility to pay for labs and provider time. 
o Is broadened to include smaller cities and rural areas in the South with heavy 
HIV burden. 
 
 Demonstration Projects are needed that are focused on: 
 
o PrEP uptake, adherence, and acceptability. 
o The efficacy and utilization of PrEP by and for women, including trans 
women, sex workers and women of color. 
Pharmaceutical Company Policy Recommendations 
 
 Gilead Sciences should: 
o Continue its investment in community-based projects supporting PrEP 
education for high-risk populations; 
o Invest in a larger PrEP mass media campaign to raise awareness and 
contribute to the normalization of PrEP use for those at risk. 
o Invest in comprehensive education for primary care providers related to 
PrEP. 
o  Improve its Medication Assistance Program (MAP) for PrEP specifically to 
allow persons under the age of 26 who are on their parent’s health insurance 
plan to access the PAP. 
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o Expand the cap on its Co-payment Assistance Program (CAP) contribution 
from $3600 to match the out-of-pocket maximum cost for Affordable Care 
Act plans ($6,850 in 2016.) 
o Provide data on PrEP utilization broken down demographically by gender, 
race, age, geography and insurance status to identify patterns of and gaps in 
PrEP uptake. 
State Policy Recommendations 
 
o State governments, particularly those in the US South, should expand their 
Medicaid programs under the Affordable Care Act. 
o Fund PrEP clinics for vulnerable populations. 
 
State and Local Health Department Policy Recommendations 
 
 State and local health departments should: 
o Fund PrEP clinics for vulnerable populations; 
o Raise awareness about PrEP in communities at risk; 
o Work with community-based organizations to educate and engage 
communities at risk about PrEP. 
o Provide comprehensive PrEP education for primary care providers. 
